Falzone Nadia, Gregory Rebecca, Aldridge Matthew, Terry Samantha Ya, Flux Glenn
1 CRUK/MRC Oxford Institute for Radiation Oncology, Oxford University, Oxford, UK.
2 Joint Department of Physics, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, Surrey, UK.
Br J Radiol. 2019 Aug;92(1100):20190117. doi: 10.1259/bjr.20190117. Epub 2019 May 20.
It has been almost a decade since the commentary by Gaze and Flux (2010) . The overarching feeling then was that no individual or organisation has taken up the challenge, nationally or internationally, of championing molecular targeted radionuclide therapy in all its aspects. Here, we report on the recent NCRI-CTRad (Clinical Trials in Molecular Radiotherapy-Tribulations and Triumphs) meeting, held in London on the 8 June 2018. The meeting was organized by the NCRI-CTRad to review the challenges and opportunities for clinical trials in molecular radiotherapy, particularly focussing on investigator-led trials that incorporate imaging and dosimetry, and to discuss how the community can move forward. This meeting was organised in conjunction with the British Nuclear Medicine Society and reflects the progress of Nuclear Medicine in the UK.
自盖兹（Gaze）和弗勒克斯（Flux）于2010年发表评论以来，已经过去了近十年。当时总体的感觉是，无论是在国内还是国际上，都没有个人或组织全面接受倡导分子靶向放射性核素治疗这一挑战。在此，我们报道2018年6月8日在伦敦举行的最近一次国家癌症研究所分子放射治疗临床试验（NCRI - CTRad）会议。该会议由NCRI - CTRad组织，旨在审视分子放射治疗临床试验所面临的挑战和机遇，尤其关注由研究者主导的纳入成像和剂量测定的试验，并讨论该领域如何向前发展。此次会议与英国核医学学会联合举办，反映了英国核医学的进展。
